ClinicalTrials.govrestricted
Sintilimab Plus Anlotinib as Second or Further-line Therapy for ES-SCLC Who Have Progressed After Anti-PD-1/L1 Therapy
ClinicalTrials.gov study NCT07022301. IPD Sharing: UNDECIDED. Countries: 0. Publications: 0.
ShareScore
20/100
Overall dataset sharing score
Score breakdown
These five areas show where the dataset supports — or may limit — practical reuse.
- Stewardship
- 8
- Harmonization
- 8
- Access
- 0
- Reuse readiness
- 0
- Engagement
- 4
Topics
Dataset details
- Repository
- ClinicalTrials.gov
- Published
- February 11, 2026
- License
- IPD-UNDECIDED
- DOI
- clinicaltrials.gov/NCT07022301
Scored with release 0.9.0
ScienceDex for faculty
Your academic CV and NIH biosketch
Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.